ACY-775

Modify Date: 2024-01-07 08:09:43

ACY-775 Structure
ACY-775 structure
Common Name ACY-775
CAS Number 1375466-18-4 Molecular Weight 330.36
Density 1.1±0.1 g/cm3 Boiling Point 589.7±45.0 °C at 760 mmHg
Molecular Formula C17H19FN4O2 Melting Point N/A
MSDS N/A Flash Point 310.4±28.7 °C

 Use of ACY-775


ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM.

 Names

Name ACY-775
Synonym More Synonyms

 ACY-775 Biological Activity

Description ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM.
Related Catalog
Target

HDAC6:7.5 nM (IC50)

HDAC1:2123 nM (IC50)

HDAC2:2570 nM (IC50)

HDAC3:11223 nM (IC50)

In Vitro In vehicle-treated cells, α-tubulin is mainly presented in the deacetylated form, while histone 3 is clearly acetylated. Upon treatment with ACY-775, a clear enhancement of the acetylation of α-tubulin is visible, while histone acetylation remains unaltered. Acetylation of α-tubulin is visualized by immunofluorescence and the intensity in the neurites of the neurons is quantified and normalized to the length of the fluorescent signal. In vehicle-treated DRG neurons, acetylated α-tubulin is already present. Upon treatment with ACY-775 the signal intensity of acetylated α-tubulin increases significantly. Significant increase in motility of mitochondria and also the total number of mitochondria within the neurites are observed compare with vehicle-treated DRG neurons. A significantly higher number of retrogradely transport mitochondria is observed in DRG neurons treated with ACY-775 compare with vehicle-treated cells[1].
In Vivo Biodistribution profiles of ACY-738, ACY-775, and tubastatin A are examined after acute dosing at 5 or 50 mg/kg over 2 h. At t=30 min after acute 50 mg/kg injection, respective plasma levels of ACY-738 and ACY-775 are 515 ng/mL (1.9 μM) and 1359 ng/mL (4.1 μM). Elimination from plasma is rapid, with plasmatic half-life of 12 min and concentration below 10 ng/mL after 2 h. Nevertheless, areas under concentration time curves for brain and plasm calculated over 2 h for both ACY-738 and ACY-775 lead to ratios >1. When ACY-738 (5 mg/kg) or ACY-775 (50 mg/kg) are administered repeatedly in wild-type mice at 24 h, 4 h, and 30 min before killing, significant increases in α-tubulin acetylation are observed in all tested brain regions[2].
Cell Assay Undifferentiated RN46A-B14 cells, a line of immortalized rat raphe neuronal precursors, are grown. They are treated with 2.5 μM ACY-738, ACY-775, tubastatin A, 0.6 μM TSA or vehicle (0.1% DMSO) for 4 h. Samples are processed using histone extraction kit and quantified using protein assay.
Animal Admin Mice are tested for immobility in the TST. At 30 min or 2 h after i.p. injection of ACY-738 (5, 50 mg/kg), ACY-775 (5, 50 mg/kg), and citalopram (0.5, 2, 20 mg/kg), a combination of the previous, or vehicle, mice are attached to the test rig and time immobile over 6 min is recorded. For open-field activity mice are injected with ACY-738 or ACY-775 at 5, 10, or 50 mg/kg or vehicle and allowed to explore. Activity is recorded[2].
References

[1]. Veronick Benoy, et al. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Neurotherapeutics. 2017 Apr; 14(2): 417-428.

[2]. Jeanine Jochems et al. Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology. 2014 Jan; 39(2): 389-400.

 Chemical & Physical Properties

Density 1.1±0.1 g/cm3
Boiling Point 589.7±45.0 °C at 760 mmHg
Molecular Formula C17H19FN4O2
Molecular Weight 330.36
Flash Point 310.4±28.7 °C
LogP 1.54
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.566
Storage condition 2-8℃

 Synonyms

Benzamide, 4-(dimethylamino)-N-[5-[(2-mercaptoacetyl)amino]pentyl]-
4-(Dimethylamino)-N-{5-[(sulfanylacetyl)amino]pentyl}benzamide